AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2059393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 to 40 mg/day for 8 weeks (after enalapril)
Number of subjects: 24
Study 2059393 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine for 8 weeks (first group)
Number of subjects: 24
Study 2059393 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril after nitrendipine for 8 weeks (second group)
Number of subjects: 24
Study 6132354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 60
Study 6132354 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 60
Study 31036114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat harvested from medial thigh (Group A)
Number of subjects: 39
Study 31036114 — intervention group
Group type: COMPARATOR
Intervention: Fat harvested from abdomen (Group B)
Number of subjects: 39
Study 28335701 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (VG)
Number of subjects: 30
Study 28335701 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CG)
Number of subjects: 30
Study 26043560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaogan Lipi Recipe (TLR), one dose per day for 12 weeks
Number of subjects: 99
Study 26043560 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one dose per day for 12 weeks
Number of subjects: 99
Study 23690237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient/intensive physician
Number of subjects: 275
Study 23690237 — intervention group
Group type: COMPARATOR
Intervention: Minimal physician intervention
Number of subjects: 275
Study 23690237 — intervention group
Group type: COMPARATOR
Intervention: Minimal patient/minimal physician
Number of subjects: 275
Study 23690237 — intervention group
Group type: COMPARATOR
Intervention: Minimal patient/intensive physician
Number of subjects: 275
Study 23690237 — intervention group
Group type: COMPARATOR
Intervention: Intensive patient/minimal physician
Number of subjects: 275
Study 21593661 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg twice daily
Number of subjects: 57
Study 21593661 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once daily
Number of subjects: 57
Study 21593661 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 57
Study 18501900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix protocol
Number of subjects: 564
Study 18501900 — intervention group
Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 564
Study 16945057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention including academic detailing, provider-specific data, educational materials for providers, and motivational materials for patients
Number of subjects: 10696
Study 16945057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose blood pressure was controlled at baseline
Number of subjects: 10696
Study 16945057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose blood pressure was not controlled at baseline
Number of subjects: 10696
Study 16945057 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 10696
Study 15261317 — intervention group
Group type: COMPARATOR
Intervention: nitroglycerin + normal saline (NS) i.v.
Number of subjects: 60
Study 15261317 — intervention group
Group type: COMPARATOR
Intervention: nitroglycerin + ephedrine 0.1 mg/kg i.v.
Number of subjects: 60
Study 15261317 — intervention group
Group type: COMPARATOR
Intervention: nitroglycerin + ephedrine 0.15 mg/kg i.v.
Number of subjects: 60
Study 15261317 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethaphan + NS i.v.
Number of subjects: 60
Study 15261317 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethaphan + ephedrine 0.1 mg/kg i.v.
Number of subjects: 60
Study 15261317 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethaphan + ephedrine 0.15 mg/kg i.v.
Number of subjects: 60
Study 10831810 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 0
Study 9083303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute vasopressin solution (0.05 U/mL)
Number of subjects: 52
Study 9083303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 52
Study 1583417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (optimal dose for 6 weeks)
Number of subjects: 42
Study 1583417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 week without medication)
Number of subjects: 42
Study 1583417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (return to medication after placebo)
Number of subjects: 42
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) 50 mg/month
Number of subjects: 30
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) 100 mg/month
Number of subjects: 30
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) 200 mg/month
Number of subjects: 30
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (TC) 250 mg/month
Number of subjects: 30
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discontinuation of DMPA
Number of subjects: 30
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA administration
Number of subjects: 30
Study 3159547 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA withdrawal
Number of subjects: 30
Study 30938101 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 24
Study 30938101 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrosurgery
Number of subjects: 24
Study 30389035 — intervention group
Group type: EXPERIMENTAL
Intervention: 16K group (busulfan area under the curve of 16,000 mumol/min)
Number of subjects: 98
Study 30389035 — intervention group
Group type: EXPERIMENTAL
Intervention: 20K group (busulfan area under the curve of 20,000 mumol/min)
Number of subjects: 98
Study 30389035 — intervention group
Group type: EXPERIMENTAL
Intervention: 20K group
Number of subjects: 98
Study 29043412 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP) 145 mg/m2 Q21d
Number of subjects: 83
Study 29043412 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 350 mg/m2 Q21d
Number of subjects: 83
Study 25391324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge exercises with a sling and micro vibrations (therapy group)
Number of subjects: 32
Study 25391324 — intervention group
Group type: COMPARATOR
Intervention: Bridge exercises with a sling without vibrations (control group)
Number of subjects: 32
Study 23279860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene intervention (training mothers for 4 weeks on control point conditions)
Number of subjects: 60
Study 23279860 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 21563962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 mg of Neuravena®
Number of subjects: 0
Study 21563962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 mg of Neuravena®
Number of subjects: 0
Study 21563962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18486257 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased basal/total daily insulin ratio (B/TD ratio) from about 0.35 to about 0.46+/‐0.12 without change of total insulin daily dose
Number of subjects: 0
Study 18486257 — intervention group
Group type: COMPARATOR
Intervention: Patients whose B/TD ratio was not changed
Number of subjects: 0
Study 16141377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) followed by carbohydrate loading (CHO)
Number of subjects: 8
Study 16141377 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HCD) followed by CHO
Number of subjects: 8
Study 16141377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) followed by CHO
Number of subjects: 8
Study 12937241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive oral ganciclovir therapy
Number of subjects: 80
Study 12937241 — intervention group
Group type: COMPARATOR
Intervention: Conventional deferred treatment (control group)
Number of subjects: 80
Study 12937241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 10636615 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 34
Study 10636615 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 34
Study 10636615 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 34
Study 9250252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide 20 mg
Number of subjects: 37
Study 9250252 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo-control)
Number of subjects: 37
Study 8330089 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey impregnated gauze
Number of subjects: 92
Study 8330089 — intervention group
Group type: COMPARATOR
Intervention: OpSite (Control)
Number of subjects: 92
Study 3735283 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial injection of 40 mg of triamcinalone acetonide
Number of subjects: 40
Study 3735283 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin, 100 mg/day
Number of subjects: 40
Study 29020193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 2677
Study 26602006 — intervention group
Group type: EXPERIMENTAL
Intervention: miniaturized CPB (mCPB)
Number of subjects: 26
Study 26602006 — intervention group
Group type: COMPARATOR
Intervention: conventional CPB (cCPB)
Number of subjects: 26
Study 26602006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mCPB and cCPB
Number of subjects: 26
Study 24809878 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 0
Study 24809878 — intervention group
Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 0
Study 24809878 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 23529570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (up to 10 mg/day)
Number of subjects: 814
Study 23529570 — intervention group
Group type: COMPARATOR
Intervention: Glipizide (up to 20 mg/day)
Number of subjects: 814
Study 23529570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814
Study 23529570 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 814
Study 20722686 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 0
Study 20722686 — intervention group
Group type: COMPARATOR
Intervention: Diet plus exercise
Number of subjects: 0
Study 20722686 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity energy expenditure
Number of subjects: 0
Study 20722686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean energy intake
Number of subjects: 0
Study 20722686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean total energy expenditure
Number of subjects: 0
Study 20722686 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in fructosamine level
Number of subjects: 0
Study 18835885 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 48
Study 18835885 — intervention group
Group type: COMPARATOR
Intervention: gum elastic bougie with Macintosh laryngoscope
Number of subjects: 48
Study 16631122 — intervention group
Group type: EXPERIMENTAL
Intervention: A1555G mutation carriers (deaf patients)
Number of subjects: 54
Study 16631122 — intervention group
Group type: EXPERIMENTAL
Intervention: A1555G mutation carriers (hearing carriers)
Number of subjects: 54
Study 16631122 — intervention group
Group type: COMPARATOR
Intervention: Control group (sporadic cases)
Number of subjects: 54
Study 14633083 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (Naf)
Number of subjects: 96
Study 14633083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride (Tam)
Number of subjects: 96
Study 14633083 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil (Naf) and Tamsulosin hydrochloride (Tam)
Number of subjects: 96
Study 14633083 — intervention group
Group type: COMPARATOR
Intervention: Naf-to-Tam and Tam-to-Naf crossover groups
Number of subjects: 96
Study 10965198 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide, pirarubicin and cisplatin)
Number of subjects: 0
Study 10965198 — intervention group
Group type: EXPERIMENTAL
Intervention: EP (etoposide and cisplatin)
Number of subjects: 0
Study 10965198 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CA125 levels <35 IU/ml
Number of subjects: 0
Study 10965198 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CA125 levels >=35 IU/ml
Number of subjects: 0
Study 10965198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pelvic lymph node metastasis
Number of subjects: 0
Study 10965198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without pelvic lymph node metastasis
Number of subjects: 0
Study 9599973 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric patients (schizophrenia)
Number of subjects: 63
Study 9599973 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 63
Study 2532986 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide and 2% miconazole
Number of subjects: 30
Study 2532986 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide alone
Number of subjects: 30
Study 744492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomeroy's Kroener's or a combination of both surgical procedures
Number of subjects: 100
Study 31564259 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS block
Number of subjects: 120
Study 31564259 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 120
Study 28698243 — intervention group
Group type: EXPERIMENTAL
Intervention: De qi group (n=43) - deep needling at SP6 with manipulation using thick needles
Number of subjects: 88
Study 28698243 — intervention group
Group type: COMPARATOR
Intervention: No de qi group (n=45) - shallow needling with no manipulation using thin needles
Number of subjects: 88
Study 28698243 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual de qi sensation (n=68, regardless of group allocation)
Number of subjects: 88
Study 24284086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-aminolevulinic acid (5-ALA)
Number of subjects: 90
Study 21176727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of roflumilast (ROF) 500 µg
Number of subjects: 12
Study 21176727 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of roflumilast (ROF) 150 µg
Number of subjects: 12
Study 18637718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% citric acid solution
Number of subjects: 116
Study 18637718 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite (NaOCl) solution
Number of subjects: 116
Study 18637718 — intervention group
Group type: EXPERIMENTAL
Intervention: 810‐nm laser energy via a 200‐microm optic fiber at 2.5 W power in pulsed mode for 5 sec
Number of subjects: 116
Study 18637718 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl, followed by laser, then citric acid, followed by laser, then NaOCl and laser
Number of subjects: 116
Study 16556612 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (including zinc)
Number of subjects: 75
Study 16556612 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (including zinc and LAB)
Number of subjects: 75
Study 16556612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12970832 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice in stroke rehabilitation
Number of subjects: 0
Study 12970832 — intervention group
Group type: EXPERIMENTAL
Intervention: Research knowledge transfer
Number of subjects: 0
Study 10928228 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct measurement of total hip BMD
Number of subjects: 46
Study 10928228 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated total hip BMD using formula: Total hip BMD = 0.48 x Neck BMD + 0.62 x Trochanteric BMD + 0.03
Number of subjects: 46
Study 9295593 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (converted from Sandimmune on a 1:1 dosing basis)
Number of subjects: 141
Study 8316578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer assessment
Number of subjects: 12
Study 2937707 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone therapy
Number of subjects: 10
Study 2937707 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of prednisolone
Number of subjects: 10
Study 31108930 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 54
Study 31108930 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Intervention (SDI)
Number of subjects: 54
Study 30167655 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Stress Reduction (MBSR) training, weekly 2-hour classes and 20 minutes of daily home practice over 8 weeks.
Number of subjects: 21
Study 30167655 — intervention group
Group type: COMPARATOR
Intervention: Active control group (details not specified).
Number of subjects: 21
Study 27576192 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program + Denneroll cervical traction device
Number of subjects: 60
Study 27576192 — intervention group
Group type: COMPARATOR
Intervention: Multimodal rehabilitation program
Number of subjects: 60
Study 24773171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (SLIT)
Number of subjects: 0
Study 24773171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22147287 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg three times a day for 10 days)
Number of subjects: 80
Study 22147287 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg three times a day for 10 days)
Number of subjects: 80
Study 22147287 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 80
Study 22147287 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 80
Study 22147287 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (follow-on prescription)
Number of subjects: 80
Study 20653798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination therapy (polypill) with aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg, and hydrochlorothiazide 12.5 mg
Number of subjects: 475
Study 20653798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 18411606 — intervention group
Group type: EXPERIMENTAL
Intervention: Local adrenaline administration into the surgical field before wound closure
Number of subjects: 121
Study 18411606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local adrenaline)
Number of subjects: 121
Study 15794389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolytic enzymes (HE)
Number of subjects: 301
Study 15794389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 12174064 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm Q‐switched Nd:YAG laser
Number of subjects: 6
Study 12174064 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm FLPDL
Number of subjects: 6
Study 12174064 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm variable pulse Nd:YAG laser
Number of subjects: 6
Study 12174064 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated segment)
Number of subjects: 6
Study 10630854 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tangential excision and skin grafting
Number of subjects: 50
Study 10630854 — intervention group
Group type: COMPARATOR
Intervention: Honey dressing
Number of subjects: 50
Study 8605133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol vaginal ring
Number of subjects: 194
Study 8605133 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine oestrogen vaginal cream
Number of subjects: 194
Study 1524045 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 240 mg/day orally for at least 2 months
Number of subjects: 150
Study 1524045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 6388425 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (600 mg daily)
Number of subjects: 104
Study 6388425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 31169066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 48
Study 31169066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 48
Study 31169066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 29052225 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks with pre‐emptive ibuprofen and paracetamol
Number of subjects: 13
Study 29052225 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks
Number of subjects: 13
Study 27207749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Delirium! intervention (16-month enhanced educational package)
Number of subjects: 215
Study 27207749 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control homes)
Number of subjects: 215
Study 24858921 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 140
Study 24858921 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 140
Study 24707449 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body resistance training with self-efficacy enhancement (UBR + SE)
Number of subjects: 64
Study 24707449 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body resistance training and health education (UBR + HE)
Number of subjects: 64
Study 24707449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined UBR + SE and UBR + HE
Number of subjects: 64
Study 24707449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined UBR groups
Number of subjects: 64
Study 24707449 — intervention group
Group type: COMPARATOR
Intervention: Gentle chair exercises and health education (CE + HE)
Number of subjects: 64